Literature DB >> 6537881

Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura.

Y S Ahn, W J Harrington, R Mylvaganam, L M Allen, L M Pall.   

Abstract

Vinca alkaloids are useful in the treatment of idiopathic thrombocytopenic purpura, a disorder in which macrophages remove platelets sensitized with antibody. Because vinca alkaloids avidly bind to platelets, drugs can be delivered selectively to macrophages. However, drugs given by bolus injection are cleared too rapidly to bind optimally to autologous platelets, and the use of allogeneic platelets loaded with drug in vitro is cumbersome, expensive, and dangerous. Therefore, slow infusions were devised to prolong the duration of enhanced plasma drug concentrations, thereby providing better conditions for in-vivo drug loading into autologous platelets. Twenty-four patients with refractory idiopathic thrombocytopenic purpura were given slow infusions; 17 had good to excellent responses. Eleven of eighteen patients who had been treated with bolus injections had better results when treated with slow infusions. Patients with improved responses had slower plasma clearance rates than did patients with poor responses. Slow infusion therapy had fewer side effects than bolus injection therapy. Slow infusions are the best method for long-term management.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6537881     DOI: 10.7326/0003-4819-100-2-192

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  Chronic idiopathic thrombocytogenic purpura.

Authors:  G F Pineo
Journal:  Can Fam Physician       Date:  1984-09       Impact factor: 3.275

3.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

4.  [Value of preoperative thrombocyte marking in patients with idiopathic thrombocytopenic purpura].

Authors:  M Gietz; W Mempel; C Clemm; E Hiller; M Heim; W Wilmanns
Journal:  Klin Wochenschr       Date:  1988-07-15

5.  Treatment of thrombocytopenia with alfa interferon.

Authors:  A M Lever; M G Brook; I Yap; H C Thomas
Journal:  Br Med J (Clin Res Ed)       Date:  1987-12-12

Review 6.  Immunosuppressant therapy of idiopathic thrombocytopenic purpura.

Authors:  Y S Ahn; W J Harrington; R Mylvaganam
Journal:  Springer Semin Immunopathol       Date:  1984

7.  Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases.

Authors:  P Fenaux; I Quiquandon; M T Caulier; M Simon; M P Walter; F Bauters
Journal:  Blut       Date:  1990-04

8.  Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors.

Authors:  B J Takasugi; A B Robertone; S E Salmon; S E Jones; D S Alberts
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

9.  Spontaneous improvement of chronic immune thrombocytopenia in children: experience of 56 patients at a single institute.

Authors:  Motohiro Kato; Katsuyoshi Koh; Akira Kikuchi; Ryoji Hanada
Journal:  Int J Hematol       Date:  2012-10-27       Impact factor: 2.490

10.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.